

# Rose Ann Padua

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2377692/publications.pdf>

Version: 2024-02-01

87  
papers

2,785  
citations

159585

30  
h-index

182427

51  
g-index

88  
all docs

88  
docs citations

88  
times ranked

3074  
citing authors

#	ARTICLE	IF	CITATIONS
1	FMS mutations in myelodysplastic, leukemic, and normal subjects.. Proceedings of the National Academy of Sciences of the United States of America, 1990, 87, 1377-1380.	7.1	217
2	RAS, FMS and p53 mutations and poor clinical outcome in myelodysplasias: a 10-year follow-up. Leukemia, 1998, 12, 887-892.	7.2	212
3	Multidrug resistance in haemopoietic cell lines, myelodysplastic syndromes and acute myeloblastic leukaemia. British Journal of Haematology, 1989, 72, 40-44.	2.5	148
4	Reactive Oxygen Species, DNA Damage, and Error-Prone Repair: A Model for Genomic Instability with Progression in Myeloid Leukemia?. Cancer Research, 2007, 67, 8762-8771.	0.9	134
5	A novel transforming gene in a human malignant melanoma cell line. Nature, 1984, 311, 671-673.	27.8	117
6	Nanofluidic proteomic assay for serial analysis of oncoprotein activation in clinical specimens. Nature Medicine, 2009, 15, 566-571.	30.7	105
7	Histone Deacetylase Inhibitors (HDI) Cause DNA Damage in Leukemia Cells: A Mechanism for Leukemia-Specific HDI-Dependent Apoptosis?. Molecular Cancer Research, 2006, 4, 563-573.	3.4	99
8	Clonal lymphocytes are detectable in only some cases of MDS. British Journal of Haematology, 1992, 81, 346-352.	2.5	84
9	Frequent expression of HAGE in presentation chronic myeloid leukaemias. Leukemia, 2002, 16, 2238-2242.	7.2	73
10	PML-RARAâ€‘targeted DNA vaccine induces protective immunity in a mouse model of leukemia. Nature Medicine, 2003, 9, 1413-1417.	30.7	72
11	Mutant N-RAS Induces Erythroid Lineage Dysplasia in Human CD34+ Cells. Journal of Experimental Medicine, 1997, 185, 1337-1348.	8.5	71
12	MULTIDRUG RESISTANCE IN LEUKAEMIA. British Journal of Haematology, 1997, 96, 659-674.	2.5	65
13	Prospective International Cohort Study Demonstrates Inability of Interim PET to Predict Treatment Failure in Diffuse Large B-Cell Lymphoma. Journal of Nuclear Medicine, 2014, 55, 1936-1944.	5.0	63
14	The application of X-chromosome gene probes to the diagnosis of myeloproliferative disease. British Journal of Haematology, 1989, 72, 530-533.	2.5	56
15	Plasmodium chabaudi: Genetics of resistance to chloroquine. Experimental Parasitology, 1981, 52, 419-426.	1.2	55
16	Translocation of the inhibitor of apoptosis protein c-IAP1 from the nucleus to the Golgi in hematopoietic cells undergoing differentiation: a nuclear export signal-mediated event. Blood, 2004, 104, 2035-2043.	1.4	55
17	Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia. Signal Transduction and Targeted Therapy, 2022, 7, 51.	17.1	54
18	Expression of the multiple drug resistance gene (mdr-1) and epitope masking in chronic lymphatic leukaemia. British Journal of Haematology, 1990, 76, 226-230.	2.5	53

#	ARTICLE	IF	CITATIONS
19	BCL-2 and Mutant NRAS Interact Physically and Functionally in a Mouse Model of Progressive Myelodysplasia. <i>Cancer Research</i> , 2007, 67, 11657-11667.	0.9	53
20	Genetics of Mefloquine Resistance in the Rodent Malaria Parasite <i>Plasmodium chabaudi</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2003, 47, 709-718.	3.2	52
21	Biochemical genetics of a new glucosephosphate isomerase allele (Gpi-1 c) from wild mice. <i>Biochemical Genetics</i> , 1978, 16, 127-143.	1.7	48
22	BCL-2 inhibition with ABT-737 prolongs survival in an NRAS/BCL-2 mouse model of AML by targeting primitive LSK and progenitor cells. <i>Blood</i> , 2013, 122, 2864-2876.	1.4	46
23	p53 activation during ribosome biogenesis regulates normal erythroid differentiation. <i>Blood</i> , 2021, 137, 89-102.	1.4	46
24	Targeted therapies in myeloid leukemia. <i>Seminars in Cancer Biology</i> , 2004, 14, 41-62.	9.6	45
25	Comparison of Newly Diagnosed and Relapsed Patients with Acute Promyelocytic Leukemia Treated with Arsenic Trioxide: Insight into Mechanisms of Resistance. <i>PLoS ONE</i> , 2015, 10, e0121912.	2.5	43
26	Transformation of mononuclear phagocytes in vivo and malignant histiocytosis caused by a novel murine spleen focus-forming virus. <i>Nature</i> , 1985, 315, 149-151.	27.8	41
27	The promyelocytic leukemia zinc finger protein down-regulates apoptosis and expression of the proapoptotic BID protein in lymphocytes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 1898-1903.	7.1	41
28	The proneural gene ASCL1 governs the transcriptional subgroup affiliation in glioblastoma stem cells by directly repressing the mesenchymal gene NDRG1. <i>Cell Death and Differentiation</i> , 2019, 26, 1813-1831.	11.2	41
29	Glutathione-s-transferase pi expression in leukaemia: a comparative analysis with mdr-1 data. <i>British Journal of Cancer</i> , 1990, 62, 209-212.	6.4	39
30	The cystic fibrosis $\Delta F508$ gene mutation and cancer. <i>Human Mutation</i> , 1997, 10, 45-48.	2.5	32
31	Rationale and efficacy of proteasome inhibitor combined with arsenic trioxide in the treatment of acute promyelocytic leukemia. <i>Leukemia</i> , 2016, 30, 2169-2178.	7.2	28
32	DNA vaccination with all-trans retinoic acid treatment induces long-term survival and elicits specific immune responses requiring CD4+ and CD8+ T-cell activation in an acute promyelocytic leukemia mouse model. <i>Blood</i> , 2010, 115, 653-656.	1.4	24
33	Methylation of the DXS255 hypervariable locus 5' CCGG site may be affected by factors other than X-chromosome activation status. <i>Genomics</i> , 1992, 14, 70-74.	2.9	23
34	Identification of JAK2 mutations in canine primary polycythemia. <i>Experimental Hematology</i> , 2011, 39, 542-545.	0.4	23
35	Engineering mouse models with myelodysplastic syndrome human candidate genes; how relevant are they?. <i>Haematologica</i> , 2013, 98, 10-22.	3.5	21
36	Lithium chloride antileukemic activity in acute promyelocytic leukemia is GSK-3 and MEK/ERK dependent. <i>Leukemia</i> , 2015, 29, 2277-2284.	7.2	19

#	ARTICLE	IF	CITATIONS
37	Retinoic acid receptor alpha1 variants, RARalpha1DeltaB and RARalpha1DeltaBC, define a new class of nuclear receptor isoforms. <i>Nucleic Acids Research</i> , 2001, 29, 4901-4908.	14.5	18
38	UV and clean air result in contamination-free PCR. <i>Leukemia</i> , 1999, 13, 1898-1899.	7.2	17
39	FMS mutations in patients following cytotoxic therapy for lymphoma. <i>Leukemia Research</i> , 1995, 19, 309-318.	0.8	16
40	ABT-737 Targets Intrinsic Apoptosis during Cooperation of BCL-2 and Oncogenic NRAS in An in Vivo Progression Model of Myelodysplasia/Acute Myeloid Leukaemia. <i>Blood</i> , 2008, 112, 848-848.	1.4	16
41	Distribution of common genetic subgroups in childhood acute lymphoblastic leukemia in four developing countries. <i>Cancer Genetics and Cytogenetics</i> , 2010, 200, 149-153.	1.0	15
42	Refractory anaemia with preleukaemic polyclonal haemopoiesis and the emergence of monoclonal erythropoiesis on disease progression. <i>British Journal of Haematology</i> , 1995, 89, 675-677.	2.5	14
43	Arsenic Trioxide Enhances the NK Cell Cytotoxicity Against Acute Promyelocytic Leukemia While Simultaneously Inhibiting Its Bio-Genesis. <i>Frontiers in Immunology</i> , 2018, 9, 1357.	4.8	14
44	Changing p53 mutations with the evolution of chronic myeloid leukaemia from the chronic phase to blast crisis. <i>Leukemia Research</i> , 1995, 19, 519-525.	0.8	13
45	Targeted immunotherapy in acute myeloblastic leukemia: from animals to humans. <i>Cancer Immunology, Immunotherapy</i> , 2005, 54, 933-943.	4.2	13
46	Multidrug resistance in leukaemia. <i>Best Practice and Research: Clinical Haematology</i> , 1992, 5, 943-960.	1.1	12
47	Biological consequences of a point mutation at codon 969 of the FMS gene. <i>Leukemia Research</i> , 1998, 22, 365-372.	0.8	12
48	Molecular, Cytogenetic and Genetic Abnormalities in MDS and Secondary AML. <i>Cancer Treatment and Research</i> , 2001, 108, 111-157.	0.5	12
49	NK Cell Mediated Cytotoxicity Against Malignant Promyelocytes Enhanced By Arsenic Trioxide: Potential Clinical Relevance. <i>Blood</i> , 2013, 122, 1455-1455.	1.4	12
50	Chromosomal assignment of c-MEL, a human transforming oncogene, to chromosome 19 (p13.2-q13.2). <i>Somatic Cell and Molecular Genetics</i> , 1986, 12, 637-640.	0.7	11
51	Alteration of the PML proto-oncogene in leukemic cells does not abrogate expression of MHC class I antigens. <i>Leukemia</i> , 1999, 13, 1295-1296.	7.2	11
52	Protocol for qRT-PCR analysis from formalin fixed paraffin embedded tissue sections from diffuse large b-cell lymphoma: Validation of the six-gene predictor score. <i>Oncotarget</i> , 2016, 7, 83319-83329.	1.8	11
53	Increased DNA Damage and Error-Prone Repair in MPD/MDS Mice with Disease Progression: Key Indicators for Increased Genomic Instability.. <i>Blood</i> , 2004, 104, 200-200.	1.4	11
54	Flow cytometric apoptosis assays indicate different types of endonuclease activity in haematopoietic cells and suggest a cautionary approach to their quantitative use. , 1998, 31, 130-136.		10

#	ARTICLE	IF	CITATIONS
55	Alternative effects of RAS and RAF oncogenes on the proliferation and apoptosis of factor-dependent FDC-P1 cells. <i>Leukemia Research</i> , 2000, 24, 47-54.	0.8	10
56	Retinoic Acid Receptor $\hat{\pm}$ (RAR $\hat{\pm}$ ) Mutations in Human Leukemia. <i>Leukemia and Lymphoma</i> , 2000, 39, 271-282.	1.3	10
57	Frequent antibody production against RAR $\hat{\pm}$ in both APL mice and patients. <i>Blood</i> , 2006, 108, 1972-1974.	1.4	10
58	GEP analysis validates high risk MDS and acute myeloid leukemia post MDS mice models and highlights novel dysregulated pathways. <i>Journal of Hematology and Oncology</i> , 2016, 9, 5.	17.0	10
59	Activation of Ha-ras in human chronic granulocytic and chronic myelomonocytic leukaemia. <i>Leukemia Research</i> , 1988, 12, 805-810.	0.8	9
60	Upregulation of p21 RAS levels in HL-60 cells during differentiation induction with DMSO, all-trans-retinoic acid and TPA. <i>Leukemia Research</i> , 1995, 19, 291-296.	0.8	9
61	Confirmation and refinement of the localisation of the c-MEL locus on chromosome 19 by physical and genetic mapping. <i>Human Genetics</i> , 1989, 81, 382-384.	3.8	8
62	Oncogene mutation and prognosis in the myelodysplastic syndromes. <i>British Journal of Haematology</i> , 2000, 111, 873-874.	2.5	8
63	A screen for RAS mutations in individuals at risk of secondary leukaemia due to occupational exposure to petrochemicals. <i>Leukemia Research</i> , 1995, 19, 299-301.	0.8	7
64	Allelic loss of the FMS gene in acute myeloid leukaemia. <i>Leukemia Research</i> , 1997, 21, 919-923.	0.8	7
65	Tracking the extramedullary PML-RAR $\hat{\pm}$ -positive cell reservoirs in a preclinical model: Biomarker of long-term drug efficacy. <i>Molecular and Cellular Probes</i> , 2013, 27, 1-5.	2.1	7
66	Elevated levels of p53 protein in the neutrophils and monocytes of a patient with chronic idiopathic thrombocytopenic purpura or possible early myelodysplasia?. <i>Leukemia Research</i> , 1995, 19, 727-731.	0.8	6
67	Alterations of the retinoic acid receptor $\hat{\pm}$ (RAR $\hat{\pm}$ ) gene in myeloid and lymphoid malignancies. <i>British Journal of Haematology</i> , 1999, 104, 738-741.	2.5	6
68	BCL-2 Inhibitor Venetoclax (ABT-199) and MEK Inhibitor GDC-0973 Synergise to Target AML Progenitors and Overcome Drug Resistance with the Use of PET Scanning in a Mouse Model of HR-MDS to Monitor Response to Treatment. <i>Blood</i> , 2018, 132, 5497-5497.	1.4	6
69	Farnesyltransferase inhibitor tipifarnib (R115777) preferentially inhibits in vitro autonomous erythropoiesis of polycythemia vera patient cells. <i>Blood</i> , 2005, 105, 3743-3745.	1.4	5
70	Localization of the NRAS:BCL-2 complex determines anti-apoptotic features associated with progressive disease in myelodysplastic syndromes. <i>Leukemia Research</i> , 2013, 37, 312-319.	0.8	5
71	BCL-2 Inhibitor ABT-737 Effectively Targets Leukemia-Initiating Cells with Differential Regulation of Relevant Genes Leading to Extended Survival in a NRAS/BCL-2 Mouse Model of High Risk-Myelodysplastic Syndrome. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10658.	4.1	4
72	DNA-mediated adjuvant immunotherapy extends survival in two different mouse models of myeloid malignancies. <i>Oncotarget</i> , 2015, 6, 32494-32508.	1.8	4

#	ARTICLE	IF	CITATIONS
73	Use of animal models for the treatment of leukemias: Efficacy of DNA vaccination combined with ATRA. <i>Discovery Medicine</i> , 2004, 4, 41-4.	0.5	4
74	In vitro drug resistance in acute myeloid and chronic B-lymphocytic leukaemic blasts and in normal blood and marrow populations. <i>Leukemia Research</i> , 1994, 18, 683-691.	0.8	2
75	A novel CSF-1 binding factor in a patient in complete remission following cytotoxic therapy for lymphoma. <i>British Journal of Haematology</i> , 1995, 89, 219-222.	2.5	2
76	Isotopic biomarker discovery and application in translational medicine. <i>Drug Discovery Today</i> , 2010, 15, 127-136.	6.4	2
77	pVAX14DNA-mediated add-on immunotherapy combined with arsenic trioxide and all-trans retinoic acid targeted therapy effectively increases the survival of acute promyelocytic leukemia mice. <i>Blood Cancer Journal</i> , 2015, 5, e374-e374.	6.2	2
78	The cystic fibrosis $\Delta$ F508 gene mutation and cancer. , 1997, 10, 45.		2
79	H RAS mutations in haematologically normal individuals. <i>The Hematology Journal</i> , 2000, 1, 399-402.	1.4	2
80	A c-DNA probe for the oncogene c-MEL (pC7 $\Delta$ 1) recognises a polymorphism with NcoI. <i>Nucleic Acids Research</i> , 1987, 15, 3940-3940.	14.5	1
81	The effect of biological heterogeneity on R-CHOP treatment outcome in diffuse large B-cell lymphoma across five international regions. <i>Leukemia and Lymphoma</i> , 2017, 58, 1178-1183.	1.3	1
82	4 Animal models of myelodysplasia: BCL-2 and mutant NRAS-mediated disease progression. <i>Leukemia Research</i> , 2007, 31, S3.	0.8	0
83	Identification of a Patient Cohort with Relapsing Diffuse Large B-Cell Lymphoma with a Low International Prognostic Index in PET/CT Using a 2-Gene (LMO2/TNFRSF9) Scoring System. <i>Acta Haematologica</i> , 2020, 143, 600-602.	1.4	0
84	Cooperation between MYC and BCL2 to Induce Lymphoma Is Uncovered in an Adult Context.. <i>Blood</i> , 2004, 104, 1530-1530.	1.4	0
85	Two Oncogenic Hits Are Required To Initiate Lymphomagenesis in Adult, but Not Neonatal Hosts.. <i>Blood</i> , 2005, 106, 2604-2604.	1.4	0
86	pVAX14 DNA, a Non-Specific DNA Vaccine, Improves Survival In An Acute Promyelocytic Leukemia (APL) Mouse Model Treated With All-Trans Retinoic Acid (ATRA) and Arsenic Trioxide (ATO) and Targets Leukemia Initiating Cells (LICs). <i>Blood</i> , 2013, 122, 235-235.	1.4	0
87	Efficacy of ABT-737, a BCL-2 Inhibitor, in an NRAS/BCL2 Mouse Model of High Risk Myelodysplasia (HR-MDS) By Targeting Pathways Identified By Gene Expression Profiling. <i>Blood</i> , 2014, 124, 3249-3249.	1.4	0